Drilldown: Medicines
More actions
Use the filters below to narrow your results.
generic:
Agomelatine (1) ·
Amoxapine (1) ·
Atorvastatin (1) ·
Clomipramine (1) ·
Desipramine (1) ·
Duloxetine (1) ·
Imipramine (1) ·
Isocarboxazid (1) ·
Levomilnacipran (1) ·
Lovastatin (1) ·
Maprotiline (1) ·
Milnacipran (1) ·
Moclobemide (1) ·
Nefazodone (1) ·
Phenelzine (1) ·
Pravastatin (1) ·
Protriptyline (1) ·
Reboxetine (1) ·
Rosuvastatin (1) ·
Sertraline (1) ·
Simvastatin (1) ·
Tianeptine (1) ·
Tranylcypromine (1) ·
Trimipramine (1)
brand:
None (1) ·
Altoprev (ER), Mevacor (discontinued US); mostly generic (1) ·
Anafranil (1) ·
Aurorix (1) ·
Crestor, Ezallor (1) ·
Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) ·
Edronax (1) ·
Fetzima (1) ·
Lipitor (1) ·
Ludiomil (1) ·
Marplan (1) ·
Nardil (1) ·
Norpramin (1) ·
Parnate (1) ·
Pravachol (1) ·
Savella (1) ·
Serzone (1) ·
Stablon (1) ·
Surmontil (1) ·
Tofranil (1) ·
Valdoxan (1) ·
Vivactil (1) ·
Zocor (1) ·
Zoloft (1)
classes: (Click arrow to add another value)
mechanism:
None (3) ·
Irreversible non-selective MAO inhibitor (3) ·
Melatonin receptor agonist; 5-HT2C antagonist (1) ·
Mu-opioid agonist; modulates glutamate AMPA receptors (1) ·
Potent serotonin reuptake inhibitor; also NRI (1) ·
Reversible inhibitor of MAO-A (1) ·
Selective norepinephrine reuptake inhibitor (3) ·
Serotonin and norepinephrine reuptake inhibitor (3) ·
Serotonin reuptake inhibitor and 5-HT2A antagonist (1) ·
Serotonin–norepinephrine reuptake inhibition (balanced) (1) ·
Serotonin–norepinephrine reuptake inhibitor (2) ·
TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) ·
Weak SRI; primarily H1/D2/alpha antagonist (1) ·
'"`UNIQ--vote-000000F7-QINU`"' Minimal CYP3A4 dependence (CYP2C9 minor) reduces drug-drug interactions; transport in and out of hepatocytes is largely via OATP1B1, making SLCO1B1 PGx genotype the most clinically actionable marker for statin-associated myopathy'"`UNIQ--ref-000000F8-QINU`"'. (1) ·
'"`UNIQ--vote-000003D1-QINU`"' SLCO1B1 polymorphism affects exposure but is most clinically actionable for simvastatin'"`UNIQ--ref-000003D2-QINU`"'. (1)
uses:
None (18) ·
Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) ·
'"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"' (1) ·
'"`UNIQ--vote-000000F9-QINU`"', '"`UNIQ--vote-000000FA-QINU`"', '"`UNIQ--vote-000000FB-QINU`"' (1) ·
'"`UNIQ--vote-00000178-QINU`"', '"`UNIQ--vote-00000179-QINU`"' (1) ·
'"`UNIQ--vote-000003D3-QINU`"', '"`UNIQ--vote-000003D4-QINU`"' (1) ·
'"`UNIQ--vote-00000805-QINU`"', '"`UNIQ--vote-00000806-QINU`"' (1)
starting dose:
None (18) ·
10-20 mg PO once daily (1) ·
10-20 mg PO once daily (5 mg in Asian ancestry, elderly, hypothyroidism, or strong CYP/SLCO1B1 interactions) (1) ·
10-20 mg PO once daily in the evening (40 mg starting allowed for high CV risk) (1) ·
20 mg PO once daily with the evening meal; titrate to 40-80 mg/d (1) ·
25 mg (1) ·
40 mg PO once daily (10-20 mg in elderly, hepatic impairment, or strong drug interactions) (1)
preparations:
fda max:
None (18) ·
200 mg/d (1) ·
40 mg/d (rarely needed; 40 mg restricted to patients not at goal on 20 mg) (1) ·
40 mg/d standard; 80 mg/d restricted to patients tolerating 80 mg for ≥12 months without myopathy (post-SEARCH 2011 FDA restriction) (1) ·
80 mg/d (2) ·
80 mg/d (40 mg/d if combined with diltiazem, verapamil, danazol; lower limits with various interactions) (1)
onset:
None (17) ·
Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) ·
LDL lowering at 1 week, max by 4 weeks (1) ·
LDL lowering at 2 weeks, max by 4 weeks (3) ·
LDL lowering at 2 weeks, max by 4 weeks; cardiovascular benefit months to years (1) ·
Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1)
duration:
halflife:
None (17) ·
14 hours (parent); 20-30 hours including active ortho- and para-hydroxylated metabolites'"`UNIQ--ref-0000001B-QINU`"' (1) ·
~12 hours (1) ·
~19 hours'"`UNIQ--ref-000000FC-QINU`"' (1) ·
~2 hours (parent and active β-hydroxy acid metabolite); pharmacodynamic effect lasts 24 hours via target turnover'"`UNIQ--ref-0000017A-QINU`"' (1) ·
~2-3 hours (parent); pharmacodynamic effect 24 hours via target turnover'"`UNIQ--ref-000003D5-QINU`"' (1) ·
~2-4 hours (parent and active β-hydroxy acid metabolite); pharmacodynamic effect 24 hours via target turnover'"`UNIQ--ref-00000807-QINU`"' (1) ·
~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1)
bioavailability:
None (17) ·
<5% (extensive hepatic first-pass; food enhances absorption of IR, hence the evening-meal dosing)'"`UNIQ--ref-00000808-QINU`"' (1) ·
<5% (extensive hepatic first-pass; statin pharmacology is hepatocellular, not systemic)'"`UNIQ--ref-0000017B-QINU`"' (1) ·
Absolute bioavailability not precisely characterized; food modestly increases exposure (1) ·
~14% (extensive hepatic first-pass)'"`UNIQ--ref-0000001C-QINU`"' (1) ·
~17% (oral; food slightly reduces absorption)'"`UNIQ--ref-000003D6-QINU`"' (1) ·
~20% (oral; hydrophilic, minimal CYP metabolism, mostly excreted unchanged in bile)'"`UNIQ--ref-000000FD-QINU`"' (1) ·
~50% (highly variable) (1)
pregnancy:
None (17) ·
Category C (1) ·
Category C'"`UNIQ--ref-0000008F-QINU`"' (1) ·
Previously Category X; FDA removed the blanket statin contraindication in pregnancy in 2021. Use individualized.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Previously Category X; FDA removed the blanket statin contraindication in pregnancy in 2021. Use individualized; lactation generally avoided.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Previously Category X; FDA removed the blanket statin contraindication in pregnancy in 2021.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (3)
Showing below up to 24 results in range #1 to #24.